Vanda Pharmaceuticals Inc (VNDA) 12.37 $VNDA
Vanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015
PR Newswire - Mon Feb 02, 6:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2014 on Thursday, February 19, 2015, before the market opens.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
PR Newswire - Thu Jan 29, 6:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 3, 2015 in New York, NY.
VNDA: 12.37 (unch)
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
PR Newswire - Fri Jan 16, 8:30AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 8,586,610 ('610 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. As described in the Orange Book, this patent covers a method of treating schizophrenia by administering Fanapt® to a patient by reducing the dose in patients who are poor metabolizers of CYP2D6. The '610 patent was issued by the United States Patent and Trademark Office in November 2013 and expires in November 2027. Prior to the '610 patent, the only patent previously listed in the Orange Book was the U.S. composition of matter patent for Fanapt®, which is currently expected to expire in November 2016.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals Up 13.2% Since SmarTrend Uptrend Call (VNDA)
Comtex SmarTrend(R) - Tue Jan 13, 12:21AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 3 months, Vanda Pharmaceuticals has returned 13.15% as of today's recent price of $12.13.
VNDA: 12.37 (unch)
Can John Paulson Bounce Back in 2015? Investments in Health Care and Pharmaceuticals Could Help
at The Street - Mon Jan 12, 8:31AM CST
Billionaire investor John Paulson's portfolio took a beating in 2014. A look at his equities holdings reveals why.
KOG: 6.56 (-0.39), ANV: 0.97 (-0.03), WLL: 38.53 (+2.41), VRX: 167.00 (-0.50), NCQ: 0.56 (+0.03), VNDA: 12.37 (unch), FDO: 77.86 (+0.31), VOD: 35.85 (+0.14), CIE: 8.90 (+0.20), AGN: 229.49 (+1.87), S: 5.23 (+0.08), SHPG: 239.82 (+6.11), AOL: 41.78 (+1.22), KMDA: 4.23 (+0.03), ABBV: 58.05 (+1.00), DG: 68.82 (+1.23), TWC: 149.74 (+2.21), TMUS: 31.75 (+0.16), VZ: 49.31 (-0.21), CMCSA: 59.47 (+1.09), OAS: 16.84 (-0.03)
Nasdaq stocks posting largest percentage decreases
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GMLP: 28.17 (+0.45), EOPN: 8.55 (-0.01), CTSO: 8.20 (+0.18), VNDA: 12.37 (unch), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37)
Vanda Pharmaceuticals Up 34.1% Since SmarTrend Uptrend Call (VNDA)
Comtex SmarTrend(R) - Mon Jan 05, 4:46PM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 2 months, Vanda Pharmaceuticals has returned 34.14% as of today's recent price of $14.38.
VNDA: 12.37 (unch)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.37 (unch), VTAE: 14.40 (+0.82), XNCR: 15.47 (-0.22)
5 Stocks Insiders Love Right Now: Vanda, Vicon and More
at The Street - Tue Dec 30, 8:40AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
HCOM: 26.76 (-0.10), VNDA: 12.37 (unch), EOG: 96.92 (+2.12), MLNK: 3.78 (+0.04), VII: 1.47 (-0.02)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), VNDA: 12.37 (unch), IMGN: 7.19 (unch), EXEL: 2.48 (+0.20)
Shares of VNDA Up 41.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 29, 10:56AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 2 months, Vanda Pharmaceuticals has returned 40.95% as of today's recent price of $15.11.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals Rises 8.17% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Dec 24, 4:42PM CST
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $13.75 to a high of $14.98. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $14.84 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 12.37 (unch)
Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 391.66 (-0.45), VNDA: 12.37 (unch), SHPG: 239.82 (+6.11), NVS: 102.20 (-0.17)
Trade-Ideas: Vanda Pharmaceuticals (VNDA) Is Today's Strong On High Relative Volume Stock
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate
VNDA: 12.37 (unch)
Critical Alerts For Vanda Pharmaceuticals, Avis, YPF, Chesapeake Energy and Baidu Released By InvestorsObserver
PR Newswire - Wed Dec 24, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for VNDA, CAR, YPF, CHK and BIDU.
BIDU: 212.13 (+7.11), CHK: 21.08 (+0.58), VNDA: 12.37 (unch), CAR: 62.30 (+1.04), YPF: 26.86 (+1.15)
Factors Driving the Equity Markets: Coverage Initiated on GoPro, Lockheed Martin, Smith & Nephew, NQ Mobile and Vanda
PR Newswire - Wed Dec 24, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including GoPro (NASDAQ: GPRO), Lockheed Martin (NYSE: LMT), Smith & Nephew (NYSE: SNN), NQ Mobile (NYSE: NQ), and Vanda (NASDAQ: VNDA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SNN: 35.82 (-0.28), GPRO: 45.27 (-0.02), LMT: 196.95 (-0.53), VNDA: 12.37 (unch), NQ: 3.95 (-0.03)
Vanda rises on settlement
at Investor's Business Daily - Tue Dec 23, 5:48PM CST
The biotech settled a lawsuit with Novartis (NVS) over its schizophrenia drug Fanapt. Late Mon., Vanda (VNDA) said its Big Pharma partner had agreed to transfer U.S. and Canadian rights of Fanapt and make a $25 mil equity investment in the firm....
VNDA: 12.37 (unch), NVS: 102.20 (-0.17)
Hertz and Green Mountain are big market movers
AP - Tue Dec 23, 3:53PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 50.79 (+1.94), BB.TO: 12.56 (+0.24), HTZ: 23.00 (-0.24), GMCR: 118.53 (+0.56), OCN: 9.10 (+0.09), NBR: 12.73 (+0.52), VNDA: 12.37 (unch), BBRY: 10.09 (+0.23), DRL: 2.31 (+0.10), BZH: 17.13 (-0.04), ENTA: 33.30 (-0.44), BA: 149.73 (+1.64), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CHK: 21.08 (+0.58), TASR: 26.96 (-0.42)
Vanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015
PR Newswire - Mon Feb 02, 6:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the fourth quarter of 2014 on Thursday, February 19, 2015, before the market opens.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
PR Newswire - Thu Jan 29, 6:00PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 3, 2015 in New York, NY.
VNDA: 12.37 (unch)
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
PR Newswire - Fri Jan 16, 8:30AM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 8,586,610 ('610 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. As described in the Orange Book, this patent covers a method of treating schizophrenia by administering Fanapt® to a patient by reducing the dose in patients who are poor metabolizers of CYP2D6. The '610 patent was issued by the United States Patent and Trademark Office in November 2013 and expires in November 2027. Prior to the '610 patent, the only patent previously listed in the Orange Book was the U.S. composition of matter patent for Fanapt®, which is currently expected to expire in November 2016.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals Up 13.2% Since SmarTrend Uptrend Call (VNDA)
Comtex SmarTrend(R) - Tue Jan 13, 12:21AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 3 months, Vanda Pharmaceuticals has returned 13.15% as of today's recent price of $12.13.
VNDA: 12.37 (unch)
Can John Paulson Bounce Back in 2015? Investments in Health Care and Pharmaceuticals Could Help
at The Street - Mon Jan 12, 8:31AM CST
Billionaire investor John Paulson's portfolio took a beating in 2014. A look at his equities holdings reveals why.
KOG: 6.56 (-0.39), ANV: 0.97 (-0.03), WLL: 38.53 (+2.41), VRX: 167.00 (-0.50), NCQ: 0.56 (+0.03), VNDA: 12.37 (unch), FDO: 77.86 (+0.31), VOD: 35.85 (+0.14), CIE: 8.90 (+0.20), AGN: 229.49 (+1.87), S: 5.23 (+0.08), SHPG: 239.82 (+6.11), AOL: 41.78 (+1.22), KMDA: 4.23 (+0.03), ABBV: 58.05 (+1.00), DG: 68.82 (+1.23), TWC: 149.74 (+2.21), TMUS: 31.75 (+0.16), VZ: 49.31 (-0.21), CMCSA: 59.47 (+1.09), OAS: 16.84 (-0.03)
Nasdaq stocks posting largest percentage decreases
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GMLP: 28.17 (+0.45), EOPN: 8.55 (-0.01), CTSO: 8.20 (+0.18), VNDA: 12.37 (unch), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37)
Vanda Pharmaceuticals Up 34.1% Since SmarTrend Uptrend Call (VNDA)
Comtex SmarTrend(R) - Mon Jan 05, 4:46PM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 2 months, Vanda Pharmaceuticals has returned 34.14% as of today's recent price of $14.38.
VNDA: 12.37 (unch)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.37 (unch), VTAE: 14.40 (+0.82), XNCR: 15.47 (-0.22)
5 Stocks Insiders Love Right Now: Vanda, Vicon and More
at The Street - Tue Dec 30, 8:40AM CST
Insiders usually buy their own shares because they think the stock is a bargain and has tremendous upside.
HCOM: 26.76 (-0.10), VNDA: 12.37 (unch), EOG: 96.92 (+2.12), MLNK: 3.78 (+0.04), VII: 1.47 (-0.02)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), VNDA: 12.37 (unch), IMGN: 7.19 (unch), EXEL: 2.48 (+0.20)
Shares of VNDA Up 41.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 29, 10:56AM CST
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on October 24th, 2014 at $10.72. In approximately 2 months, Vanda Pharmaceuticals has returned 40.95% as of today's recent price of $15.11.
VNDA: 12.37 (unch)
Vanda Pharmaceuticals Rises 8.17% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Dec 24, 4:42PM CST
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $13.75 to a high of $14.98. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $14.84 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 12.37 (unch)
Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 391.66 (-0.45), VNDA: 12.37 (unch), SHPG: 239.82 (+6.11), NVS: 102.20 (-0.17)
Trade-Ideas: Vanda Pharmaceuticals (VNDA) Is Today's Strong On High Relative Volume Stock
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate
VNDA: 12.37 (unch)
Critical Alerts For Vanda Pharmaceuticals, Avis, YPF, Chesapeake Energy and Baidu Released By InvestorsObserver
PR Newswire - Wed Dec 24, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for VNDA, CAR, YPF, CHK and BIDU.
BIDU: 212.13 (+7.11), CHK: 21.08 (+0.58), VNDA: 12.37 (unch), CAR: 62.30 (+1.04), YPF: 26.86 (+1.15)
Factors Driving the Equity Markets: Coverage Initiated on GoPro, Lockheed Martin, Smith & Nephew, NQ Mobile and Vanda
PR Newswire - Wed Dec 24, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including GoPro (NASDAQ: GPRO), Lockheed Martin (NYSE: LMT), Smith & Nephew (NYSE: SNN), NQ Mobile (NYSE: NQ), and Vanda (NASDAQ: VNDA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SNN: 35.82 (-0.28), GPRO: 45.27 (-0.02), LMT: 196.95 (-0.53), VNDA: 12.37 (unch), NQ: 3.95 (-0.03)
Vanda rises on settlement
at Investor's Business Daily - Tue Dec 23, 5:48PM CST
The biotech settled a lawsuit with Novartis (NVS) over its schizophrenia drug Fanapt. Late Mon., Vanda (VNDA) said its Big Pharma partner had agreed to transfer U.S. and Canadian rights of Fanapt and make a $25 mil equity investment in the firm....
VNDA: 12.37 (unch), NVS: 102.20 (-0.17)
Hertz and Green Mountain are big market movers
AP - Tue Dec 23, 3:53PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 50.79 (+1.94), BB.TO: 12.56 (+0.24), HTZ: 23.00 (-0.24), GMCR: 118.53 (+0.56), OCN: 9.10 (+0.09), NBR: 12.73 (+0.52), VNDA: 12.37 (unch), BBRY: 10.09 (+0.23), DRL: 2.31 (+0.10), BZH: 17.13 (-0.04), ENTA: 33.30 (-0.44), BA: 149.73 (+1.64), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CHK: 21.08 (+0.58), TASR: 26.96 (-0.42)
